<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168142">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01872299</url>
  </required_header>
  <id_info>
    <org_study_id>FP7/2007-2013, No. 241558</org_study_id>
    <secondary_id>241558</secondary_id>
    <nct_id>NCT01872299</nct_id>
  </id_info>
  <brief_title>Studies Investigating Co-morbidities Aggravating Heart Failure</brief_title>
  <acronym>SICA-HF</acronym>
  <official_title>Studies Investigating Co-morbidities Aggravating Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Hull</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wroclaw Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IRCCS San Raffaele</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Almazov Federal Center of Heart, Blood and Endocrinology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Moscow State University of Medicine and Dentistry</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Siberian Branch of the Russian Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Russian Cardiology Research and Production Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University Clinic of Pulmonary and Allergic Diseases Golnik</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Silesian Centre for Heart Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SICA-HF is a prospective, multicentre, multinational, longitudinal, pathophysiological
      evaluation study, which is being conducted in 11 centres across six countries. SICA-HF
      receives funding from the European commission's Seventh Framework Programme (FP7/2007-2013)
      under grant agreement no. 241558 (SICA-HF) and from the Russian Ministry of Science and
      Education within the file transfer protocol &quot;R&amp;D in priority fields of the S&amp;T complex of
      Russia 2007-2012&quot; under state contract number 02.527.11.0007. The aim of SICA-HF is to
      provide detailed characteristics of co-morbidities of heart failure at baseline and over
      time, particularly with regards to obesity, cachexia, and type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>4 Years</target_duration>
  <primary_outcome>
    <measure>Prevalence, incidence, persistence and phenotype of obesity, cachexia and type 2 diabetes in patients with chronic heart failure.</measure>
    <time_frame>March 31, 2014</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in exercise capacity and cardiorespiratory reflex control</measure>
    <time_frame>March 31, 2014</time_frame>
    <safety_issue>No</safety_issue>
    <description>To describe patterns of exercise capacity and cardiorespiratory reflex control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of body composition and its changes over time</measure>
    <time_frame>March 31, 2014</time_frame>
    <safety_issue>No</safety_issue>
    <description>To analyse body composition and its changes over time in patients with chronic heart failure and type 2 diabetes, obesity or cachexia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and prevalence of sleep-disordered breathing and its impact on the clinical severity in patients with chronic heart failure</measure>
    <time_frame>March 31, 2014</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of impaired vascular reactivity on impaired skeletal muscle metabolic and functional capacity, including its underlying mechanisms</measure>
    <time_frame>March 31, 2014</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of metabolic status in patients with heart failure and type 2 diabetes, obesity and cachexia</measure>
    <time_frame>March 31, 2014</time_frame>
    <safety_issue>No</safety_issue>
    <description>To describe the interplay and metabolic signalling pathways between adipose tissue, skeletal muscle, the bone marrow and the heart in patients with heart</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Heart Failure</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Healthy control subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heart failure without co-morbidities</arm_group_label>
    <description>Patients with a clinical diagnosis of chronic heart failure without co-morbidities</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heart failure with co-morbidities</arm_group_label>
    <description>Patients with a clinical diagnosis of chronic heart failure with co-morbidities</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type 2 diabetes mellitus</arm_group_label>
    <description>Patients with type 2 diabetes mellitus and without heart failure</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, serum, plasma, DNA, biopsies from fat and muscle.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients and controls will be recruited from hospitals' outpatients' departments and/or
        via advertisements; in-patients are permitted if clinically stable.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Clinical diagnosis of heart failure;

          -  Objective evidence of cardiac dysfunctions as evidenced by at least ONE of the
             following:

               -  left ventricular ejection fraction ≤ 40%;

               -  left atrial dimension &gt;4.0 cm (or &gt;2.5 cm/m in height)

               -  NT-proBNP &gt;400 pg/ml [&gt;47.3 pmol/l] (or BNP &gt;150 pg/ml)

          -  Current treatment with loop diuretics;

          -  Age &gt;18 years;

          -  Willingness to provide informed consent

        Exclusion criteria:

          -  Congenital heart disease;

          -  Any life-threatening disease other than heart failure;

          -  Active malignancy of any type, or history of a malignancy within previous 5 years;

          -  Previous heart transplantation;

          -  Intra-venous therapy for heart failure given within the previous 72 hours;

          -  Severe neuro-muscular disease;

          -  History of unstable angina, myocardial infarction or stroke within 3 months prior to
             the study;

          -  Pregnancy;

          -  Treatment with immunosuppressive therapy, e.g. steroids for rheumatoid arthritis or
             obstructive lung disease;

          -  Significant renal dysfunction, defined as serum creatinine &gt;250 μmol/L [&gt;2.8 mg/dL];

          -  Severe liver disease, defined as any liver function tests &gt;3 times the upper limit of
             normal;

          -  Unable to understand and comply with protocol or to give informed consent.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan D Anker, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité- University Medicine Berlin, Campus Virchow Klinikum</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephan von Haehling, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Charité- University Medicine Berlin, Campus Virchow Klinikum</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Cleland, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Hull</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Piotr Ponikowski, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Wroclaw Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giuseppe Rosano, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>IRCCS San Raffaele</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jens Jordan, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eugeniy Shlyakhto, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Almazov Federal Center for Heart, Blood &amp; Endocrinology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vsevolod Tkachuk, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Lomonosov Moscow State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rostislav Karpov, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Institute of Cardiology, Siberian Branch, Russian Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yelena Parfyonova, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Russian Cardiology Research and Production Complex</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mitja Lainscak, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Clinic of Respiratory and Allergic diseases Golnik</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Piotr Rozentryt, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Silesian Centre for Heart Diseases</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefan D Anker, MD, PhD</last_name>
    <phone>004930450</phone>
    <phone_ext>553463</phone_ext>
    <email>s.anker@cachexia.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephan von Haehling, MD, PhD</last_name>
    <phone>004930450</phone>
    <phone_ext>553507</phone_ext>
    <email>stephan.von.haehling@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité- University Medicine Berlin, Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan D Anker, MD, PhD</last_name>
      <phone>004930450553463</phone>
      <email>s.anker@cachexia.de</email>
    </contact>
    <investigator>
      <last_name>Stefan D Anker, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Jordan, MD, PhD</last_name>
      <phone>0049511 532</phone>
      <phone_ext>2821</phone_ext>
      <email>jordan.jens@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>Jens Jordan, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS San Raffaele</name>
      <address>
        <city>Rom</city>
        <zip>00163</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Rosano, MD, PhD</last_name>
      <phone>00396 660</phone>
      <phone_ext>581</phone_ext>
      <email>giuseppe.rosano@sanraffaele.it</email>
    </contact>
    <investigator>
      <last_name>Guiseppe Rosano, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wroclaw, Medical University</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-367</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Ponikowski, MD, PhD</last_name>
      <phone>004871 7660</phone>
      <phone_ext>237</phone_ext>
      <email>piotrponikowski@4wsk.pl</email>
    </contact>
    <investigator>
      <last_name>Piotr Ponikowski, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Silesian Centre for Heart Diseases</name>
      <address>
        <city>Zabrze</city>
        <zip>41800</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Rozentryt, MD, PhD</last_name>
      <phone>0048 3237 33</phone>
      <phone_ext>619</phone_ext>
      <email>p.rozentryt@sccs.pl</email>
    </contact>
    <investigator>
      <last_name>Piotr Rozentryt, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lomonosov Moscow State University</name>
      <address>
        <city>Moscow</city>
        <state>Moskow</state>
        <zip>119192</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vsevolod Tkachuk, PhD</last_name>
      <phone>007495</phone>
      <phone_ext>9328814</phone_ext>
      <email>tkachuk@fbm.msu.ru</email>
    </contact>
    <investigator>
      <last_name>Vsevolod Tkachuk, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Russian Cardiology Research and Production Complex</name>
      <address>
        <city>Moscow</city>
        <zip>12552</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yelena Parfyonova, MD, PhD</last_name>
      <phone>007495</phone>
      <phone_ext>4146783</phone_ext>
      <email>yeparfyon@cardio.ru</email>
    </contact>
    <investigator>
      <last_name>Yelena Parfyonova, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Almazov Federal Center for Heart, Blood &amp; Endocrinology</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugeniy Shlyakhto, MD, PhD</last_name>
      <phone>007921</phone>
      <phone_ext>7413718</phone_ext>
      <email>shlyakhto@inbox.ru</email>
    </contact>
    <investigator>
      <last_name>Eugeniy Shlyakhto, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Cardiology, Siberian Branch, Russian Academy of Medical Sciences</name>
      <address>
        <city>Tomsk</city>
        <zip>634012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rostislav Karpov, MD, PhD</last_name>
      <phone>007382 2</phone>
      <phone_ext>553449</phone_ext>
      <email>tvk@cardio.tsu.ru</email>
    </contact>
    <investigator>
      <last_name>Rostislav Karpov, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Clinic of Respiratory and Allergic diseases Golnik</name>
      <address>
        <city>Golnik</city>
        <zip>4204</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitja Lainscak, MD, PhD</last_name>
      <phone>003864 2569</phone>
      <phone_ext>141</phone_ext>
      <email>mitja.lainscak@guest.arnes.si</email>
    </contact>
    <investigator>
      <last_name>Mitja Lainscak, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of HULL</name>
      <address>
        <city>Hull</city>
        <zip>HU16 5JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Cleland, MD, PhD</last_name>
      <phone>00441482</phone>
      <phone_ext>461776</phone_ext>
      <email>J.G.Cleland@hull.ac.uk</email>
    </contact>
    <investigator>
      <last_name>John Cleland, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Slovenia</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.sica-hf.com/</url>
    <description>Study home page</description>
  </link>
  <reference>
    <citation>von Haehling S, Lainscak M, Doehner W, Ponikowski P, Rosano G, Jordan J, Rozentryt P, Rauchhaus M, Karpov R, Tkachuk V, Parfyonova Y, Zaritskey AY, Shlyakhto EV, Cleland JG, Anker SD. Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). J Cachexia Sarcopenia Muscle. 2010 Dec;1(2):187-194. Epub 2010 Dec 17.</citation>
    <PMID>21475696</PMID>
  </reference>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 18, 2013</lastchanged_date>
  <firstreceived_date>May 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Prof. Stefan D Anker</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
